AstraZeneca Launches Zegfrovy in U.S. After Accelerated FDA Approval
AstraZeneca’s U.S. launch of Zegfrovy opens a potential oncology revenue stream, but accelerated approval leaves clinical confirmation as a …
AbbVie’s INTREPID Data Strengthens the Case for Dermatology Pipeline Diversification
AbbVie’s Phase 3 INTREPID results show stronger hidradenitis suppurativa responses than the comparator, adding depth beyond Humira and Skyri…
Biohaven Stock Jumps as FDA Accepts Troriluzole Resubmission and Ono Deal Adds Validation
Biohaven’s $BHVN shares jumped 25% after FDA acceptance of its troriluzole resubmission, while an Ono deal added cash and external validatio…
Cencora’s $2.4 Billion American Oncology Network Deal Pushes Deeper Into Cancer Care
Cencora’s $2.4 billion acquisition of American Oncology Network marks a strategic move from drug distribution into direct cancer-care provis…
Unicycive Stock Gains 6.8% After FDA Accepts OLC Resubmission
Unicycive shares rose 6.8% premarket after the FDA accepted its OLC resubmission, creating a regulatory event-driven setup ahead of a formal…
BioCryst’s New Orladeyo Formulation Expands Rare-Disease Growth Opportunity
FDA approval of a new Orladeyo oral pellet formulation gives BioCryst a fresh catalyst that could broaden access and extend the product’s co…
Jemperli’s Accelerated FDA Approval Could Expand AnaptysBio’s Royalty Opportunity
Jemperli’s expanded FDA approval could strengthen AnaptysBio’s royalty opportunity while limiting its exposure to clinical-trial execution.
Alcon’s Neurotech Acquisition Deepens Its Push Into Ophthalmic Pharmaceuticals
Alcon’s acquisition of Neurotech Pharmaceuticals could broaden its ophthalmic drug pipeline and expand its focus beyond eye-care devices.
Cencora’s $2.4 Billion Oncology Acquisition Tests the Case for Vertical Integration
Cencora’s $2.4 billion American Oncology Network deal expands its role from drug distribution into oncology care delivery.
Novo Nordisk’s CagriSema Delivers 25% Weight Loss in Women, Raising Stakes in the GLP-1 Market
Novo Nordisk’s CagriSema produced 25% weight loss in women in a late-stage analysis, sharpening focus on its next-generation obesity franchi…
Ultragenyx Stock Plunges More Than 40% After Angelman Syndrome Drug Fails Phase III Trial
Ultragenyx shares plunged more than 40% after apazunersen failed both primary and secondary endpoints in a Phase III Angelman syndrome trial…
Ultragenyx Shares Sink More Than 40% After Apazunersen Fails Phase 3 Trial
Ultragenyx shares fell more than 40% after apazunersen failed both Phase 3 endpoints, spotlighting biotech’s binary clinical risk.











